MABTAS 500

Mabtas 500mg Injection contains rituximab, a monoclonal antibody used to treat a variety of serious health conditions, particularly those involving abnormal B-cell activity. It plays a critical role in the management of certain cancers, autoimmune diseases, and inflammatory disorders. This medication works by targeting the CD20 protein found on the surface of B-lymphocytes, helping to destroy these cells when they become cancerous or contribute to harmful immune responses.

Clinically, Mabtas is administered either alone or in combination with other therapies to manage non-Hodgkin’s lymphoma and chronic lymphocytic leukemia—both cancers that arise from B-cells. It’s also prescribed for adults with moderate to severe rheumatoid arthritis, especially when other treatments have proven ineffective. In autoimmune vasculitis conditions like granulomatosis with polyangiitis and microscopic polyangiitis, Mabtas is used in both adults and children over 2 years of age. Additionally, it is beneficial in treating pemphigus vulgaris, a rare autoimmune disorder characterized by painful skin and mucosal blistering.

Before starting treatment with Mabtas, it is crucial to disclose any history of hepatitis B, immune system disorders, ongoing infections, or heart/lung issues to your healthcare provider. Since rituximab suppresses parts of the immune system, it may increase vulnerability to infections and certain complications. It is not recommended during pregnancy or while breastfeeding due to potential risks to the fetus or infant.

While effective, Mabtas may cause side effects—most notably, infusion-related reactions that can range from mild (like itching or dizziness) to severe (such as chest pain, throat swelling, or breathing difficulties). These typically occur during or within 24 hours of administration and require immediate medical attention. Other possible effects include low blood cell counts, infections, gastrointestinal disturbances, and changes in blood pressure.

Due to its immunosuppressive effects, patients are advised to use effective contraception during treatment and for up to a year after the final dose. Regular monitoring by a healthcare professional is essential throughout the course of therapy to ensure safety and optimal response to the medication.